News coverage about IQVIA (NYSE:IQV) has been trending positive this week, according to Accern. Accern rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IQVIA earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 47.1973661125142 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Hold Recommendation?: IQVIA Holdings Inc. (IQV) (nasdaqplace.com)
- First Week of July 20th Options Trading For IQVIA Holdings (IQV) (nasdaq.com)
- Analysts Expect IQVIA (IQV) Will Post Quarterly Sales of $2.46 Billion (americanbankingnews.com)
- IQVIA (IQV) Expected to Announce Earnings of $1.25 Per Share (americanbankingnews.com)
- IQVIA bails out buyers by cancelling US$1bn block (ifre.com)
Several equities analysts have issued reports on IQV shares. Zacks Investment Research lowered IQVIA from a “hold” rating to a “sell” rating in a research note on Tuesday, February 20th. Piper Jaffray Companies reissued a “hold” rating and issued a $103.00 price target on shares of IQVIA in a research note on Thursday, February 15th. ValuEngine raised IQVIA from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Argus boosted their price target on IQVIA from $110.00 to $112.00 and gave the company a “buy” rating in a research note on Monday, April 9th. Finally, Goldman Sachs Group raised IQVIA from a “neutral” rating to a “buy” rating in a research note on Friday, April 13th. Seven analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. IQVIA has a consensus rating of “Buy” and an average target price of $110.47.
IQVIA (NYSE:IQV) last issued its earnings results on Wednesday, May 2nd. The medical research company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.07. IQVIA had a return on equity of 13.35% and a net margin of 13.07%. The company had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.42 billion. The firm’s revenue was up 34.1% compared to the same quarter last year. equities research analysts anticipate that IQVIA will post 5.06 earnings per share for the current fiscal year.
In related news, Director Michael J. Evanisko sold 816 shares of the company’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $100.00, for a total transaction of $81,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $100.00, for a total value of $1,000,000.00. The disclosure for this sale can be found here. Insiders have sold 12,527 shares of company stock worth $1,257,834 over the last ninety days. 6.00% of the stock is owned by insiders.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.